Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05322967
Other study ID # VGFOUREG-939529
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 25, 2022
Est. completion date December 1, 2023

Study information

Verified date April 2023
Source Vastra Gotaland Region
Contact Kristina B Boström, Prof, MD
Phone 0702409091
Email kristina.a.bengtsson@vgregion.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized clinical trials with cross-over design to evaluate changes in blood pressure, renal function (creatinine, estimated glomerular filtration), LDL and HDL-cholesterol after taking antihypertensive drugs in the morning or at bedtime. Blood pressure will be estimated by ambulatory blood pressure measurements. There will be a shift in time of drug intake after 8 weeks for each participant. Approximately 100 individuals aged 40-75 years and on stable anti-hypertensive treatment and blood pressure <150/95 mm Hg will be recruited. No new drugs will be introduced during the study.


Description:

High blood pressure (hypertension, HT) is very common and can lead to serious cardiovascular complications and premature death. Despite effective drug treatment many patients do not reach the blood pressure goal. No new antihypertensive drugs have been developed lately, so there is a need for other strategies to increase attainment of goals and diminish the rate of complications. The circadian rhythm can affect sleep, body temperature, hormone levels, metabolism and the effect of drugs. The impact of antihypertensive treatment in the short and long run was described in a large randomized study in primary health care where individuals with hypertension were randomly assigned to take the drugs in the morning or at bedtime. Intake at bedtime resulted in lower blood pressure, better kidney function and lower LDL-cholesterol. Further, after a mean time follow-up of 6 years a 50% reduction of cardiovascular death was seen. There was by time running a difference in antihypertensive drugs and also co-morbidity between the groups. Despite this, there is a need to investigate if chronotherapy might play a role in antihypertensive care. The aim of the study is to investigate the effect of intake of drugs in the morning compared to at bed-time. Methods: Patients 40-75 years, will be recruited from two primary health care centers and one clinic of internal medicine. Medical history, current medication will be recorded. Office blood pressure, body height and weight, ECG and ambulatory blood pressure measurement (ABPM) will be performed. Blood will be analyzed for fasting blood glucose, LDL and HDL-cholesterol and creatinine. After inclusion in the study the patients are randomly, by clinic, allocated to take their antihypertensive drugs in the morning or at bed-time during 8 week. The ordinary medication is used during the study period. The patients are instructed to keep a diary on wake-up and bed-times, side effects, sleep quality and other experiences during therapy. After 8 weeks the investigations at base-line are repeated and a visual analogue scale on sleep, daytime tiredness and urine voiding is recorded. The patients shift to intake of medication on the opposite time of day for 8 weeks. The study is completed with a repeated investigation as above. The analyses of data is performed by researchers of the team that are not aware of the patients' allocation. The diaries will be a base for later in-depth-interviews with a part of the patients. The analyses will be intention-to-treat using appropriate methods for the data. Office blood pressure, blood lipids and kidney function at baseline, 8 and 16 weeks, as well as sleep duration, urine voiding at night will be analyzed. ABPM will be analyzed using mean blood pressure around-the-clock, daytime and nighttime blood pressure, dipping and morning surge.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2023
Est. primary completion date December 1, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of hypertension - Stable antihypertensive treatment at least 8 weeks prior to inclusion - One to four antihypertensive drugs Exclusion Criteria: - Atrial fibrillation/flutter - Diabetes - Previous stroke or TIA - Heart failure - Ischemic heart disease - Peripheral artery disease - Malignant disease with less than one year expected survival - Inability to follow study protocol (for instance shift work)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Time of ordinary antihypertensive medication intake
Time of ordinary antihypertensive medication intake

Locations

Country Name City State
Sweden Sahlgrenska University Hospital, Mölndal Gothenburg
Sweden Närhälsan Billingen Primary Health Care Centre Skövde
Sweden Närhälsan Norrmalm Primary Health Care Centre Skövde

Sponsors (2)

Lead Sponsor Collaborator
Vastra Gotaland Region Swedish Heart Lung Foundation

Country where clinical trial is conducted

Sweden, 

References & Publications (8)

2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension: Erratum. J Hypertens. 2019 Feb;37(2):456. doi: 10.1097/HJH.0000000000002026. No abstract available. — View Citation

Bilo G, Grillo A, Guida V, Parati G. Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects. Integr Blood Press Control. 2018 May 24;11:47-56. doi: 10.2147/IBPC.S130277. eCollection 2018. — View Citation

Bowles NP, Thosar SS, Herzig MX, Shea SA. Chronotherapy for Hypertension. Curr Hypertens Rep. 2018 Sep 28;20(11):97. doi: 10.1007/s11906-018-0897-4. Erratum In: Curr Hypertens Rep. 2018 Dec 4;21(1):1. — View Citation

Callaway E, Ledford H. Medicine Nobel awarded for work on circadian clocks. Nature. 2017 Oct 2;550(7674):18. doi: 10.1038/nature.2017.22736. No abstract available. — View Citation

Fujiwara T, Hoshide S, Yano Y, Kanegae H, Kario K. Comparison of morning vs bedtime administration of the combination of valsartan/amlodipine on nocturnal brachial and central blood pressure in patients with hypertension. J Clin Hypertens (Greenwich). 2017 Dec;19(12):1319-1326. doi: 10.1111/jch.13128. Epub 2017 Nov 5. — View Citation

Hermida RC, Crespo JJ, Dominguez-Sardina M, Otero A, Moya A, Rios MT, Sineiro E, Castineira MC, Callejas PA, Pousa L, Salgado JL, Duran C, Sanchez JJ, Fernandez JR, Mojon A, Ayala DE; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020 Dec 21;41(48):4565-4576. doi: 10.1093/eurheartj/ehz754. — View Citation

Hermida RC. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project. Chronobiol Int. 2016;33(7):906-36. doi: 10.1080/07420528.2016.1181078. Epub 2016 May 24. — View Citation

Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Difference in score of Epworth sleepiness scale between 8 and 16 weeks Epworth sleepiness scale score registered by the patients according to time of antihypertensive drug intake 8 and 16 weeks
Other Perceived side effects 8 weeks Perceived side effects registered by the patients (VAS) according to time of antihypertensive drug intake 8 weeks
Other Perceived side effects 16 weeks Perceived side effects registered by the patients (VAS) according to time of antihypertensive drug intake 16 weeks
Primary 24 hours blood pressure changes between 8 and 16 weeks. Ambulatory blood pressure changes between 8 and 16 weeks. Systolic and diastolic mean blood pressure level. 8 and 16 weeks
Primary Change of dipping of blood pressure between 8 and 16 weeks. Ratio between daytime and nighttime blood pressure registered after 8 and 16 weeks. Systolic and diastolic mean blood pressure level. 8 and 16 weeks
Secondary Daytime blood pressure changes between 8 and 16 weeks. Ambulatory daytime blood pressure registered after 8 and 16 weeks. Systolic and diastolic mean blood pressure level. 8 and 16 weeks
Secondary Nighttime blood pressure changes between 8 and 16 weeks. Ambulatory nighttime blood pressure registered after 8 and 16 weeks. Systolic and diastolic mean blood pressure level. 8 and 16 weeks
Secondary Office blood pressure changes between 8 and 16 weeks. Office blood pressure registered after 8 and 16 weeks. Systolic and diastolic mean blood pressure level. 8 and 16 weeks
Secondary Difference in morning surge of blood pressure between 8 and 16 weeks. Occurrence of morning (yes/no) 8 and 16 weeks
Secondary Difference in LDL cholesterol levels between 8 and 16 weeks. LDL cholesterol changes according to time of intake of antihypertensive drugs 8 and 16 weeks
Secondary Difference in HDL cholesterol levels between 8 and 16 weeks. HDL cholesterol changes according to time of intake of antihypertensive drugs 8 and 16 weeks
Secondary Difference in total cholesterol levels between 8 and 16 weeks. Total cholesterol changes according to time of intake of antihypertensive drugs 8 and 16 weeks
Secondary Difference in p-creatinine levels between 8 and 16 weeks. P-creatinine changes according to time of intake of antihypertensive drugs 8 and 16 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A